{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:47:17Z","timestamp":1762256837728,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["860245"],"award-info":[{"award-number":["860245"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.radonc.2025.110908","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:14:14Z","timestamp":1745579654000},"page":"110908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["L19-IL2 reverts radiation-induced lymphopenia in a mouse model of lung cancer"],"prefix":"10.1016","volume":"208","author":[{"given":"\u00c8lia","family":"Prades-Sagarra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasja G.","family":"Lieuwes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rianne","family":"Biemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Schuitmaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan J.","family":"van Hoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Staut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Verhaegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Yaromina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig J.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110908_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2023.03.002","article-title":"Radio-induced lymphopenia in the era of anti-cancer immunotherapy","volume":"378","author":"de Kermenguy","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.radonc.2025.110908_b0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2025.110908_b0015","article-title":"Understanding the impact of radiation-induced lymphopenia: Preclinical and clinical research perspectives","volume":"49","author":"Prades-Sagarra","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0025","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.21037\/atm-21-2150","article-title":"Risk factors for radiation induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy","volume":"9","author":"Chen","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.radonc.2025.110908_b0030","article-title":"Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques","volume":"30","author":"Nowicka","year":"2024","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0035","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/j.ijrobp.2021.07.727","article-title":"Risk factors for radiation induced lymphopenia in patients with breast cancer: does radiotherapy technique matter?","volume":"111","author":"Chen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2021.01.034","article-title":"Risk and impact of radiation related lymphopenia in lung cancer: A systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0045","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0050","doi-asserted-by":"crossref","first-page":"14372","DOI":"10.1038\/s41598-023-41301-3","article-title":"Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery","volume":"13","author":"Yoon","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110908_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109934","article-title":"Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"189","author":"Yang","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2021.01.022","article-title":"Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy","volume":"154","author":"Friedes","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2025.110908_b0065","article-title":"Severe radiation-induced lymphopenia attenuates the benefit of durvalumab after concurrent chemoradiotherapy for NSCLC","volume":"3","author":"Jing","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2025.110908_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2022.01.007","article-title":"Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy","volume":"168","author":"Cho","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0075","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2025.110908_b0080","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1414119","article-title":"The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses","volume":"7","author":"Rekers","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2025.110908_b0085","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1158\/1078-0432.CCR-14-2676","article-title":"Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects","volume":"21","author":"Zegers","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110908_b0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1186\/s12885-020-07055-1","article-title":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial","volume":"20","author":"Lieverse","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110908_b0095","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ijrobp.2014.07.004","article-title":"A longitudinal evaluation of partial lung irradiation in mice by using a dedicated image-guided small animal irradiator","volume":"90","author":"Granton","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.radonc.2019.06.034","article-title":"Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity","volume":"141","author":"Spiegelberg","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0105","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acaf45","article-title":"Roadmap for precision preclinical x-ray radiation studies","volume":"68","author":"Verhaegen","year":"2023","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2025.110908_b0110","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.radonc.2017.11.016","article-title":"ESTRO ACROP: Technology for precision small animal radiotherapy research: Optimal use and challenges","volume":"126","author":"Verhaegen","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0115","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.zemedi.2014.02.004","article-title":"A review of treatment planning for precision image-guided photon beam pre-clinical animal radiation studies","volume":"24","author":"Verhaegen","year":"2014","journal-title":"Zeitschrift f\u00fcr Medizinische Physik"},{"key":"10.1016\/j.radonc.2025.110908_b0120","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ijrobp.2021.06.001","article-title":"First multimodal, three-dimensional, image-guided total marrow irradiation model for preclinical bone marrow transplantation studies","volume":"111","author":"Zuro","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0125","doi-asserted-by":"crossref","first-page":"17180","DOI":"10.1038\/s41598-019-53562-y","article-title":"Ultra high dose rate (35\u2009Gy\/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome","volume":"9","author":"Venkatesulu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110908_b0130","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1158\/0008-5472.CAN-05-0786","article-title":"Radiation damage to the heart enhances early radiation-induced lung function loss","volume":"65","author":"van Luijk","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2025.110908_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100812","article-title":"Radiation-induced lymphopenia does not impact treatment efficacy in a mouse tumor model","volume":"31","author":"Telarovic","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.radonc.2025.110908_b0140","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.ijrobp.2020.12.004","article-title":"Effect of Interleukin-7 on radiation-induced lymphopenia and its antitumor effects in a mouse model","volume":"109","author":"Byun","year":"2021","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1445951","article-title":"Systemic depletion of lymphocytes following focal radiation to the brain in a murine model","volume":"7","author":"Piotrowski","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2025.110908_b0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001764","article-title":"Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy","volume":"9","author":"Olivo Pimentel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2025.110908_b0155","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.3390\/ijms23095066","article-title":"Eosinophils and lung cancer: from bench to bedside","volume":"23","author":"Sibille","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2025.110908_b0160","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4049\/jimmunol.145.3.873","article-title":"Role of IL-5 in IL-2-induced eosinophilia. In vivo and in vitro expression of IL-5 mRNA by IL-2","volume":"145","author":"Yamaguchi","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2025.110908_b0165","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2014-07-587493","article-title":"Interleukin-5\u2013producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy","volume":"124","author":"Van Gool","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.radonc.2025.110908_b0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.2910540103","article-title":"In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5","volume":"54","author":"Rivoltini","year":"1993","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2025.110908_b0175","doi-asserted-by":"crossref","first-page":"11984","DOI":"10.1038\/s41598-024-62662-3","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy","volume":"14","author":"Yin","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2025.110908_b0180","doi-asserted-by":"crossref","first-page":"18584","DOI":"10.1073\/pnas.1901562116","article-title":"Neutrophils promote tumor resistance to radiation therapy","volume":"116","author":"Wisdom","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.radonc.2025.110908_b0185","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ijrobp.2020.11.053","article-title":"Toxicity of L19-interleukin 2 combined with stereotactic body radiation therapy: a phase 1 study","volume":"109","author":"Van Limbergen","year":"2021","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0190","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00262-019-02383-z","article-title":"A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients","volume":"68","author":"Weide","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2025.110908_b0195","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","article-title":"The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110908_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051362","article-title":"Immune checkpoint inhibitors for lung cancer treatment: a review","volume":"9","author":"Onoi","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.radonc.2025.110908_b0205","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.radonc.2025.110908_b0210","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3389\/fimmu.2017.00572","article-title":"PD-1 blockade promotes emerging checkpoint inhibitors in enhancing T cell responses to allogeneic dendritic cells","volume":"8","author":"Stecher","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2025.110908_b0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110908_b0220","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijrobp.2020.02.633","article-title":"Radiation-induced lymphopenia predicts poorer prognosis in patients with breast cancer: a post hoc analysis of a randomized controlled trial of postmastectomy hypofractionated radiation therapy","volume":"108","author":"Sun","year":"2020","journal-title":"Internat J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110908_b0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.radonc.2020.07.025","article-title":"A tumor-immune interaction model for hepatocellular carcinoma based on measured lymphocyte counts in patients undergoing radiotherapy","volume":"151","author":"Sung","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.radonc.2021.02.029","article-title":"Hematological toxicity in patients with solid malignant tumors treated with radiation \u2013 Temporal analysis, dose response and impact on survival","volume":"158","author":"Terrones-Campos","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110908_b0235","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab6c41","article-title":"4D blood flow model for dose calculation to circulating blood and lymphocytes","volume":"65","author":"Hammi","year":"2020","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2025.110908_b0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025002038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:40:25Z","timestamp":1762256425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025002038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":48,"alternative-id":["S0167814025002038"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110908","relation":{},"ISSN":["0167-8140"],"issn-type":[{"type":"print","value":"0167-8140"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L19-IL2 reverts radiation-induced lymphopenia in a mouse model of lung cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110908"}}